View ValuationAtmofizer Technologies 将来の成長Future 基準チェック /06現在、 Atmofizer Technologiesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Machinery 収益成長79.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 28Atmofizer Technologies Inc., Annual General Meeting, Jun 23, 2026Atmofizer Technologies Inc., Annual General Meeting, Jun 23, 2026.Board Change • Dec 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Michael Galloro was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 11High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Sep 27Atmofizer Technologies Inc., Annual General Meeting, Nov 25, 2022Atmofizer Technologies Inc., Annual General Meeting, Nov 25, 2022.お知らせ • Aug 26Atmofizer Technologies Inc. Announces Latest Independent Test ResultsAtmofizer Technologies Inc. announced the latest testing performed by a third-party laboratory on Atmofizer ONE technology demonstrated a greater than 4-log reduction (> 99.99%) in specifically targeted microorganisms, including gram-positive bacteria, gram-negative bacteria, and enveloped virus. The Atmofizer ONE is now marketed subject to the U.S. Food and Drug Administration's "Enforcement Policy for Sterilizers, Disinfectant Devices, and Air Purifiers During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency" (March 2020). Atmofizer's patented agglomeration technology is designed to: Aggregate airborne nanoparticles into more-addressable particulates; Use acoustic pressure to cluster the smallest airborne particulates and microorganisms, before exposure to ultraviolet light, Increase the size of airborne ultra-fine particles, Not emit ozone, or use ionization, Reduce household odors. Atmofizer ONE Performance Update: Atmofizer Efficacy Claims: 99.99% reduction of Klebsiella Aerogenes [gram-negative bacteria], 99.99% reduction of Staphylococcus Epidermis [gram-positive bacteria], 99.99% reduction of Phi-6 Bacteriophage [enveloped virus, Surrogate for SARS-CoV-2]. Atmofizer SARS-CoV-2 Specific Efficacy Claims: Atmofizer reduces airborne SARS-CoV-2, Atmofizer destroys over 99.99% SARS-CoV-2 without a filter, Atmofizer destroys SARS-CoV-2 by over 99.99% in 45 minutes. These results are based on third-party laboratory tests at 180 minutes of continuous device operation. The Food and Drug Administration (FDA) has not evaluated Atmofizer technology. Atmofizer ONE has not been reviewed or approved by the FDA. SARS-CoV-2 data is based on Third-Party Testing of Phi-6 Bacteriophage, a surrogate microorganism for SARS-CoV-2.お知らせ • May 12Atmofizer Technologies Inc. Announces Latest Test Data and Expansion of Research and Testing Team in Toronto LabAtmofizer Technologies Inc. announce the Company's test results of its airborne nanoparticle agglomeration engine. Recent test results at Atmofizer'sToronto lab have shown the Company's technology, before the use of an air filter, reduced the number of airborne ultra-fine particles smaller than one micron by 81.7%, while doubling particles sized above 2.5 microns. The Company says this is significant scientifically and medically, as it shows the removal of the smallest nanoscopic airborne particles (including toxic industrial pollution, smoke, and infectious disease). These particles are small enough that they can enter the bloodstream and get into the brain and vital organs directly through being inhaled into the lungs. Particles smaller than 2.5 microns are commonly regarded as the measure of air quality because they pose the risk to humans and animals. Doubling the amount of particles above 2.5 microns shows that the smaller particles are effectively being agglomerated together into larger clusters by the Company's technology. These larger clusters are typically more easily filtered by the body and common air filters. It is also significant that these results were without the use of a filter. The Company has also added additional staff to its Toronto testing facility to focus on applying its agglomeration technology into mobile (transport vehicles) and HVAC aftermarket applications. The additional staff will enable the Company to test and evaluate new Atmofizer airflow configurations and prototypes more quickly.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. Independent Director Michael Galloro was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Jan 18Kemper Confirms Successful Test of Atmofizer Technology Improving Industrial Fume ExtractionAtmofizer Technologies Inc. announced the completion of initial tests by Kemper GmbH. The air purification industry has largely focused on developing new filters that catch smaller particles. The challenge is that the tighter the filters the more energy is required to push air through and the most performant filters, HEPA are not recyclable or reusable so they end up in the landfills. Atmofizer's technology works by using ultrasonic waves to agglomerate the smallest particles into larger clusters to more effectively filter and neutralize harmful particles using ultraviolet light. The mission of Atmofizer is to bring clean air and water to the world.お知らせ • Jan 06Atmofizer Technologies Inc. Announces Indoor Agriculture Testing for Mold ReductionAtmofizer Technologies Inc. announced that, following a pilot project, Atmofizer will begin secondary testing of its agglomeration technology with SANlight products in Austria. Atmofizer's technology uses proprietary sound wave technology to agglomerate microscopic airborne particles making them easier to capture and neutralize with UV light. SANlight is a leader in LED lighting technology for indoor gardening (better: horticultural LED lighting).お知らせ • Dec 29Atmofizer to Release Its Latest "Back-To-Work" Product SolutionAtmofizer Technologies Inc. announced that it will attend the 2022 Consumer Electronics Show in Las Vegas, Nevada. The Company will be located at booth #52946 in The Venetian Convention and Expo Center from January 4, 2022 until January 8, 2022. Atmofizer intends to use the CES stage to release its latest "back-to-work" product solution, connect with new distributors and collaborate with integrators, including some of the world's largest appliance manufacturers.Recent Insider Transactions • Dec 03Insider recently sold CA$5.0m worth of stockOn the 29th of November, Catherine Defrancesco sold around 986k shares on-market at roughly CA$5.10 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$4.8m more than they bought in the last 12 months.お知らせ • Dec 01Catherine Brewer DeFrancesco acquired 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO).Catherine Brewer DeFrancesco acquired 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO) on November 22, 2021. As part of the agreement, Catherine Brewer DeFrancesco acquired 6.05 million common shares of Atmofizer Technologies. Prior to the acquisition, Brewer DeFrancesco had control and direction over an aggregate of 2.848 million common shares. The aggregate 8.898 million common shares now controlled and directed by Brewer DeFrancesco represents approximately 12.04% of the issued and outstanding common shares on a non-diluted basis of Atmofizer Technologies. Catherine Brewer DeFrancesco completed the acquisition of 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO) on November 22, 2021.Board Change • Nov 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Atmofizer Technologies は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CNSX:ATMO - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2024N/A000N/A9/30/2024N/A000N/A6/30/2024N/A000N/A3/31/2024N/A-1-1-1N/A12/31/2023N/A-1-1-1N/A9/30/2023N/A-13-1-1N/A6/30/2023N/A-17-1-1N/A3/31/2023N/A-22-3-3N/A12/31/20220-28-3-3N/A9/30/20221-32-6-6N/A6/30/20221-29-7-7N/A3/31/20221-26-11-5N/A12/31/20210-21-12-7N/A9/30/20210-7-11-5N/A6/30/20210-5-9-3N/A3/31/2021N/A-3-3-3N/A12/31/2020N/A-1-1-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ATMOの予測収益成長が 貯蓄率 ( 2.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ATMOの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ATMOの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ATMOの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ATMOの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ATMOの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YCapital-goods 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/05/27 19:32終値2025/02/27 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Atmofizer Technologies Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Peter-Thilo HaslerSphene Capital GmbH
お知らせ • Apr 28Atmofizer Technologies Inc., Annual General Meeting, Jun 23, 2026Atmofizer Technologies Inc., Annual General Meeting, Jun 23, 2026.
Board Change • Dec 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Michael Galloro was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 11High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Sep 27Atmofizer Technologies Inc., Annual General Meeting, Nov 25, 2022Atmofizer Technologies Inc., Annual General Meeting, Nov 25, 2022.
お知らせ • Aug 26Atmofizer Technologies Inc. Announces Latest Independent Test ResultsAtmofizer Technologies Inc. announced the latest testing performed by a third-party laboratory on Atmofizer ONE technology demonstrated a greater than 4-log reduction (> 99.99%) in specifically targeted microorganisms, including gram-positive bacteria, gram-negative bacteria, and enveloped virus. The Atmofizer ONE is now marketed subject to the U.S. Food and Drug Administration's "Enforcement Policy for Sterilizers, Disinfectant Devices, and Air Purifiers During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency" (March 2020). Atmofizer's patented agglomeration technology is designed to: Aggregate airborne nanoparticles into more-addressable particulates; Use acoustic pressure to cluster the smallest airborne particulates and microorganisms, before exposure to ultraviolet light, Increase the size of airborne ultra-fine particles, Not emit ozone, or use ionization, Reduce household odors. Atmofizer ONE Performance Update: Atmofizer Efficacy Claims: 99.99% reduction of Klebsiella Aerogenes [gram-negative bacteria], 99.99% reduction of Staphylococcus Epidermis [gram-positive bacteria], 99.99% reduction of Phi-6 Bacteriophage [enveloped virus, Surrogate for SARS-CoV-2]. Atmofizer SARS-CoV-2 Specific Efficacy Claims: Atmofizer reduces airborne SARS-CoV-2, Atmofizer destroys over 99.99% SARS-CoV-2 without a filter, Atmofizer destroys SARS-CoV-2 by over 99.99% in 45 minutes. These results are based on third-party laboratory tests at 180 minutes of continuous device operation. The Food and Drug Administration (FDA) has not evaluated Atmofizer technology. Atmofizer ONE has not been reviewed or approved by the FDA. SARS-CoV-2 data is based on Third-Party Testing of Phi-6 Bacteriophage, a surrogate microorganism for SARS-CoV-2.
お知らせ • May 12Atmofizer Technologies Inc. Announces Latest Test Data and Expansion of Research and Testing Team in Toronto LabAtmofizer Technologies Inc. announce the Company's test results of its airborne nanoparticle agglomeration engine. Recent test results at Atmofizer'sToronto lab have shown the Company's technology, before the use of an air filter, reduced the number of airborne ultra-fine particles smaller than one micron by 81.7%, while doubling particles sized above 2.5 microns. The Company says this is significant scientifically and medically, as it shows the removal of the smallest nanoscopic airborne particles (including toxic industrial pollution, smoke, and infectious disease). These particles are small enough that they can enter the bloodstream and get into the brain and vital organs directly through being inhaled into the lungs. Particles smaller than 2.5 microns are commonly regarded as the measure of air quality because they pose the risk to humans and animals. Doubling the amount of particles above 2.5 microns shows that the smaller particles are effectively being agglomerated together into larger clusters by the Company's technology. These larger clusters are typically more easily filtered by the body and common air filters. It is also significant that these results were without the use of a filter. The Company has also added additional staff to its Toronto testing facility to focus on applying its agglomeration technology into mobile (transport vehicles) and HVAC aftermarket applications. The additional staff will enable the Company to test and evaluate new Atmofizer airflow configurations and prototypes more quickly.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. Independent Director Michael Galloro was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Jan 18Kemper Confirms Successful Test of Atmofizer Technology Improving Industrial Fume ExtractionAtmofizer Technologies Inc. announced the completion of initial tests by Kemper GmbH. The air purification industry has largely focused on developing new filters that catch smaller particles. The challenge is that the tighter the filters the more energy is required to push air through and the most performant filters, HEPA are not recyclable or reusable so they end up in the landfills. Atmofizer's technology works by using ultrasonic waves to agglomerate the smallest particles into larger clusters to more effectively filter and neutralize harmful particles using ultraviolet light. The mission of Atmofizer is to bring clean air and water to the world.
お知らせ • Jan 06Atmofizer Technologies Inc. Announces Indoor Agriculture Testing for Mold ReductionAtmofizer Technologies Inc. announced that, following a pilot project, Atmofizer will begin secondary testing of its agglomeration technology with SANlight products in Austria. Atmofizer's technology uses proprietary sound wave technology to agglomerate microscopic airborne particles making them easier to capture and neutralize with UV light. SANlight is a leader in LED lighting technology for indoor gardening (better: horticultural LED lighting).
お知らせ • Dec 29Atmofizer to Release Its Latest "Back-To-Work" Product SolutionAtmofizer Technologies Inc. announced that it will attend the 2022 Consumer Electronics Show in Las Vegas, Nevada. The Company will be located at booth #52946 in The Venetian Convention and Expo Center from January 4, 2022 until January 8, 2022. Atmofizer intends to use the CES stage to release its latest "back-to-work" product solution, connect with new distributors and collaborate with integrators, including some of the world's largest appliance manufacturers.
Recent Insider Transactions • Dec 03Insider recently sold CA$5.0m worth of stockOn the 29th of November, Catherine Defrancesco sold around 986k shares on-market at roughly CA$5.10 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$4.8m more than they bought in the last 12 months.
お知らせ • Dec 01Catherine Brewer DeFrancesco acquired 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO).Catherine Brewer DeFrancesco acquired 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO) on November 22, 2021. As part of the agreement, Catherine Brewer DeFrancesco acquired 6.05 million common shares of Atmofizer Technologies. Prior to the acquisition, Brewer DeFrancesco had control and direction over an aggregate of 2.848 million common shares. The aggregate 8.898 million common shares now controlled and directed by Brewer DeFrancesco represents approximately 12.04% of the issued and outstanding common shares on a non-diluted basis of Atmofizer Technologies. Catherine Brewer DeFrancesco completed the acquisition of 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO) on November 22, 2021.
Board Change • Nov 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.